1. Home
  2. MLYS vs ACIC Comparison

MLYS vs ACIC Comparison

Compare MLYS & ACIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • ACIC
  • Stock Information
  • Founded
  • MLYS 2019
  • ACIC 1999
  • Country
  • MLYS United States
  • ACIC United States
  • Employees
  • MLYS N/A
  • ACIC N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • ACIC Property-Casualty Insurers
  • Sector
  • MLYS Health Care
  • ACIC Finance
  • Exchange
  • MLYS Nasdaq
  • ACIC Nasdaq
  • Market Cap
  • MLYS 1.0B
  • ACIC 556.0M
  • IPO Year
  • MLYS 2023
  • ACIC N/A
  • Fundamental
  • Price
  • MLYS $15.00
  • ACIC $10.70
  • Analyst Decision
  • MLYS Strong Buy
  • ACIC Buy
  • Analyst Count
  • MLYS 4
  • ACIC 1
  • Target Price
  • MLYS $27.00
  • ACIC $16.00
  • AVG Volume (30 Days)
  • MLYS 922.1K
  • ACIC 242.2K
  • Earning Date
  • MLYS 08-12-2025
  • ACIC 08-06-2025
  • Dividend Yield
  • MLYS N/A
  • ACIC 4.64%
  • EPS Growth
  • MLYS N/A
  • ACIC 3.21
  • EPS
  • MLYS N/A
  • ACIC 1.49
  • Revenue
  • MLYS N/A
  • ACIC $302,261,000.00
  • Revenue This Year
  • MLYS N/A
  • ACIC N/A
  • Revenue Next Year
  • MLYS N/A
  • ACIC $37.63
  • P/E Ratio
  • MLYS N/A
  • ACIC $7.32
  • Revenue Growth
  • MLYS N/A
  • ACIC 23.92
  • 52 Week Low
  • MLYS $8.24
  • ACIC $8.82
  • 52 Week High
  • MLYS $18.38
  • ACIC $15.08
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 50.99
  • ACIC 47.93
  • Support Level
  • MLYS $13.44
  • ACIC $10.64
  • Resistance Level
  • MLYS $14.94
  • ACIC $11.16
  • Average True Range (ATR)
  • MLYS 0.66
  • ACIC 0.26
  • MACD
  • MLYS 0.11
  • ACIC 0.04
  • Stochastic Oscillator
  • MLYS 73.84
  • ACIC 51.58

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About ACIC American Coastal Insurance Corporation

American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.

Share on Social Networks: